European Archives - Page 336 of 1657 - European Medical Journal

Very Low-Dose Multi-Nut Oral Immunotherapy Promising in Children with Multiple Food Allergies

Very low-dose multi-nut oral immunotherapy significantly increased tolerance in children with multiple nut allergies, with a favourable safety profile and no epinephrine use.

Review of the International Urologic Research Society (IURES) 2025 Congress

HOSTED AT the Hilton Dalaman Sarıgerme Hotel, Muğla, Türkiye, from 6th–9th November 2025, the International Urologic Research Society…

RARP in Patients with a History of TUR-P

Radical prostatectomy in patients with a history of transurethral resection of the prostate (TUR-P) can be technically challenging due to…

EMJ Urology 13 [Supplement 2] 2025

Want to know what’s shaping the future of urology? The IURES Journal is here! Access expert insights from the 2025 Congress…

Risks of RARP in Patients Receiving Antiplatelet and/or Anticoagulant Therapy

The use of antiplatelet and/or anticoagulant medications has increased due to irregular diets, limited physical activity, and an ageing…

Investigation of Gene Expression Levels in Patients with Non-metastatic Prostate Cancer Undergoing Radical Prostatectomy

Prostate cancer (PCa) is one of the most common malignancies in men and a major cause of cancer-related death worldwide. PCa has a…

A Rare Vascular Anomaly in a Patient with a Kidney Tumour: Left Common Iliac Vein Draining Into the Left Renal Vein

The classic triad of renal cell carcinoma (flank pain, haematuria, and a palpable abdominal mass) is observed in only 9% of patients. When…

Multifactorial Comparison of fURS and Mini-PNL Outcomes in the Treatment of Hard Renal Pelvic Stones

This study aimed to perform a multifactorial comparison of the surgical outcomes of mini-percutaneous nephrolithotomy (mini-PNL) and…

MRI-Cognitive Transperineal Prostate Biopsy Under Local Anaesthesia

MRI-cognitive transperineal prostate biopsy (TPBx) performed under local anaesthesia (LA) is increasingly adopted as a minimally…

Elafibranor Shows Promise for Primary Sclerosing Cholangitis

Phase II ELMWOOD trial shows elafibranor is well tolerated and improves liver biochemistry and pruritus in primary sclerosing cholangitis, supporting further trials.